Kidney disease Urological and Genital Diseases Other disorders of kidney and ureter, not elsewhere classified
Conditions
Interventions
1. Continuous veno-venous haemofiltration (CVVH) mode without heparin administration
2. Continuous veno-venous haemodiafiltration (CVVHDF) mode without heparin administration
3. Continuous veno-venous
Sponsors
Gambro Industries (France)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients requiring continuous renal replacement therapy (CRRT) 2. Patients aged 18 and over, either sex 3. Patients weighing 30 - 120 kg 4. Patients having signed a written consent (informed consent) to participate in the study or, in case the patient is unable to understand and/or sign the consent form, written consent from a relative or, failing which, a person of trust
Exclusion criteria
Exclusion criteria: 1. Suspicion of heparin-induced thrombocytopenia 2. Pregnancy 3. Patients requiring therapeutic anticoagulation for other indications e.g. valvular surgery or extracorporeal ventricular assist devices 4. Patients under guardianship 5. Patients anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week. These patients can eventually be included in a later more stable phase. 6. Current enrolment in another trial which could impact the successful completion of this study 7. Unconscious patients for whom no relative or person of trust can give consent for treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study. 8. Patients with high bleeding risk according to investigator and that cannot be treated with heparin. These patients should not be included in the therapy group continuous veno-venous haemodiafiltration (CVVHDF) with heparin administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Filter lifespan, defined as the time period between patient?s connection and filter disconnection. Filter clotting will be detected by following transmembrane pressure (TMP) and Filter Pressure Drop (FPD). | — |
Secondary
| Measure | Time frame |
|---|---|
| Follow-up of adverse events (AE)/serious adverse events (SAE), assessed throughout the treatment. | — |
Countries
Belgium
Outcome results
None listed